Search Results
Jul 18, 2025, 08:45 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders
The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Jul 18, 2025, 06:32 ET Weekly Recap: 14 Health Press Releases You Need to See
Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis PigmentosaIf approved, MCO-010 has the potential to be the standard of care for retinitis pigmentosa,
More news about: PR Newswire
Jul 18, 2025, 06:00 ET SRPT INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ("Duchenne"), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges
More news about: Robbins Geller Rudman & Dowd LLP
Jul 17, 2025, 18:06 ET SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 17, 2025, 17:31 ET Facioscapulohumeral Muscular Dystrophy Market Gearing Up for Outstanding Expansion Across the 7MM During the Forecast Period (2025-2034) | DelveInsight
Roughly 80% of individuals carrying the FSHD gene mutation experience symptoms, while the remaining 20% are asymptomatic, either showing no signs or only very mild symptoms that may go unnoticed
More news about: DelveInsight Business Research, LLP
Jul 17, 2025, 14:18 ET As Gene Editing Advances, CureSHANK Urges Families to "Start Genetic"
with children experiencing neurodevelopmental delays or unanswered health concerns. This movement comes on the heels of a groundbreaking milestone in gene editing: the first documented cure of an infant with an incurable genetic condition, as reported in the New England Journal of Medicine. With
More news about: CureSHANK
Jul 17, 2025, 11:15 ET Patient-Derived Xenograft Model Market Size at USD 1.12 Billion in 2031, Forecasted to Grow at 13.4% CAGR Through 2031 | The Insight Partners
to further study tumor biology and immuno-oncology. Surging Technological Advancements in PDX models Innovations such as CRISPR gene editing, next-generation sequencing, and enhanced imaging techniques have improved the precision and complexity of PDX models. These developments enable
More news about: The Insight Partners
Jul 17, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jul 17, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Jul 17, 2025, 09:00 ET 10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery
cancers. Unlike traditional methods that require tissues to be broken down, 10x Genomics' Xenium platform uniquely enables researchers to visualize gene activity directly within individual cells in intact tissues. This approach generates a comprehensive and precise molecular-level map, clearly illustrating
More news about: 10x Genomics, Inc.
Jul 17, 2025, 09:00 ET The Gross Law Firm Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Jul 17, 2025, 08:30 ET Alexandria Real Estate Equities, Inc. Wins Its First International TOBY (The Outstanding Building of the Year) Award in Life Science Category for 8 Davis Drive Anchoring the Alexandria Center for Advanced Technologies Megacampus in Research Triangle
biomanufacturing, and next-generation scientific and technological innovation. Home to a diverse mix of entities advancing complex modalities such as cell and gene therapy and radiopharmaceuticals, the campus is thoughtfully designed to enhance innovation and enable its tenants to attract and retain the brightest
More news about: Alexandria Real Estate Equities, Inc.
Jul 17, 2025, 01:50 ET Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
Enrolment is ongoing in GNT-018-IDES, a Phase 2 trial in Crigler Najjar to evaluate the efficacy and safety of Genethon's gene therapy, GNT-0003 following pre-treatment with imlifidase. The Phase 1b trial SRP-9001-104 with Sarepta remains on track
More news about: Hansa Biopharma AB
Jul 17, 2025, 01:43 ET Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
Enrolment is ongoing in GNT-018-IDES, a Phase 2 trial in Crigler Najjar to evaluate the efficacy and safety of Genethon's gene therapy, GNT-0003 following pre-treatment with imlifidase. The Phase 1b trial SRP-9001-104 with Sarepta remains on track
More news about: Hansa Biopharma AB
Jul 16, 2025, 14:41 ET VMX 2026 Program Now Live: "World Classic - Celebrating the Champions of Care" Offers 1,200 Hours of Continuing Education for Veterinary Professionals
World Classic will celebrate the passion, precision and perseverance veterinary professionals bring to their work everyday," Gene O'Neill, NAVC CEO Building on record-breaking momentum from VMX 2025 — where nearly 30,000 attendees from 87 countries and 712 exhibitors
More news about: North American Veterinary Community
Jul 16, 2025, 12:05 ET Expanded Research Tool to Crack the Code on Parkinson's, the Fastest-Growing Neurodegenerative Disease
Atlas provides intuitive data visualization and exploration tools, enabling scientists to identify, investigate, and understand brain cell types and gene expression. It's part of the
More news about: Aligning Science Across Parkinson's
Jul 16, 2025, 09:00 ET Pivot Bio Expands World-Class Scientific Advisory Board to Advance the Future of Crop Nutrition
understanding of nitrogen use efficiency through pioneering time-based gene network analysis. Her lab's development of predictive network models and their functional validation in plants—combined with 10 patents on nitrogen-responsive gene networks—provides the scientific blueprint for creating crops that
More news about: Pivot Bio, Inc
Jul 16, 2025, 09:00 ET Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit
Development Summit, being held July 14-16, 2025, in Boston, MA. "Mutations of the MC4R gene, leading to protein misfolding and impaired trafficking, are the leading cause of severe early-onset genetic obesity," commented Sharath
More news about: Congruence Therapeutics
Jul 16, 2025, 09:00 ET National Organization for Rare Disorders (NORD) Announces 2025 Industry Innovation and Rare Impact Award Honorees
treatment to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).PTC Therapeutics for KEBILIDI™: the first-ever gene therapy approved in the United States that is directly administered to the brain for the treatment of children and
More news about: National Organization for Rare Disorders (NORD®)
Jul 16, 2025, 07:10 ET Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda
Nasal, Pulmonary & Other Non-Injectable TechnologiesCell & Gene DeliveryExcipient InnovationNovel Device TechnologiesNovel Injectable & Non-Injectable TechnologiesCell, Gene & Novel Biologics DeliverySelf-Injection Devices, Syringes,
More news about: Partnership Opportunities in Drug Delivery (PODD)
Jul 16, 2025, 07:05 ET RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
[email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided
More news about: Robbins Geller Rudman & Dowd LLP
Jul 16, 2025, 06:00 ET Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules
KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and
More news about: Klotho Neurosciences, Inc.
Jul 16, 2025, 03:14 ET TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model
trials span geographic atrophy secondary to age-related macular degeneration, diabetic macular edema, retinal vein occlusion, neurotrophic keratitis, and gene therapy programs in retinitis pigmentosa, underscoring the team's therapeutic depth and ability to support sponsors, big or small, from first-in-human
More news about: TFS HealthScience
Jul 16, 2025, 02:56 ET TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model
trials span geographic atrophy secondary to age-related macular degeneration, diabetic macular edema, retinal vein occlusion, neurotrophic keratitis, and gene therapy programs in retinitis pigmentosa, underscoring the team's therapeutic depth and ability to support sponsors, big or small, from first-in-human
More news about: TFS HealthScience
Jul 15, 2025, 22:32 ET Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors
FocusThe first trial in the NCI program will investigate CX-5461 as a single agent in patients with and without homologous recombination deficiency (HRD) gene mutations, evaluating its ability to induce the Rad51 response. The study also aims to identify additional biomarkers associated with synthetic lethality
More news about: Senhwa Biosciences, Inc.